angiodynamics

Fourth Quarter and Full Year 2026 Earnings Results

July 14, 2026

Forward looking statements

Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2026. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported pro forma results, adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

Q4 FY 2026 Key Takeaways

Continued commercial and operational execution drives AngioDynamics' accelerated and profitable growth.

YoY Revenue Growth*

Total	Med Tech	Med Device
+8.0%	+16.7%	+1.1%

Med Tech YoY Revenue Growth*

Auryon	Mech Thrombectomy	NanoKnife Probes
+14.4%	-1.1%	+47.0%

Continued Execution

- Net sales of $86.6M, +8.0% YoY growth
- Med Tech segment sales of $41.8M, +16.7% YoY growth
- Med Device segment sales of $44.8M, +1.1% YoY growth

Focus on Profitability

- Pro forma Adjusted EBITDA of $3.3M

Balance Sheet Strength

- Ended quarter with $53.9M in Cash
- Zero debt with flexibility of revolving line of credit
- Generated ~$17.5M of cash from operations in the quarter
- Will generate positive cash flow from operations in FY27

*All growth rates are pro forma

Q4 FY 2026 Financial Snapshot

Net Sales



Segment Revenue Contribution



Segment Gross Margin



FY 2026 Key Takeaways

Continued commercial and operational execution drives AngioDynamics' accelerated and profitable growth.

YoY Revenue Growth*

Total	Med Tech	Med Device
+9.4%	+18.4%	+2.5%

Med Tech YoY Revenue Growth*

Auryon	Mech Thrombectomy	NanoKnife Probes
+17.7%	13.4%	+28.7%

Continued Execution

- Net sales of $320.2M, +9.4% YoY growth
- Med Tech segment sales of $150.0M, +18.4% YoY growth
- Med Device segment sales of $170.2M, +2.5% YoY growth

Focus on Profitability

- Pro forma Adjusted EBITDA** of $13.2M

Balance Sheet Strength

- Ended fiscal year with $53.9M in Cash
- Zero debt with flexibility of revolving line of credit
- Generated ~$3.1M of cash from operations in the year
- Will generate positive cash flow from operations in FY27

*All growth rates are pro forma

** Pro forma Adjusted EBITDA excludes the $5.0 million milestone payment received from Spectrum Vascular in Q3 of FY 2026

FY 2026 Financial Snapshot

Net Sales



Segment Revenue Contribution



Segment Gross Margin



Demonstrated Med Tech Growth Execution



Q4 FY 2026 MedTech Performance Snapshot

+16.7% growth driven by solid commercial execution and continued portfolio adoption

AURYON

Q4 FY 2026	Sales ($M)	YoY Growth
Total Auryon	$17.8	14.4%

ALPHAVAC

ANGIOVAC

Q4 FY 2026	Sales ($M)	YoY Growth
AlphaVac	$4.2	38.4%
AngioVac	$6.9	-15.8%
Total Mech Thromb.	**$11.1**	**-1.1%**
Unifuse	$1.0	-44.4%
Total Thrombus Mgmt.	**$12.1**	**-7.0%**

NANOKNIFE Irreversible Electroporation (IRE) PROSTATE

Q4 FY 2026	Sales ($M)	YoY Growth
Disposables	$8.4	47.0%
Capital	$3.4	132.5%
Total NanoKnife	**$11.8**	**64.5%**

Key Highlights

- **Auryon**: Double-digit growth for the 20th straight quarter, driven by our hospital atherectomy shift, customer base expansion, and early international adoption.
- **Mechanical Thrombectomy**: Continued strong demand with near-term catalysts expected from AlphaReturn and infective endocarditis IDE approvals.
- **NanoKnife**: Strong growth on record prostate volumes and probe demand, with capital placements set to lift utilization over time.

Full Year FY 2026 MedTech Performance Snapshot

+18.4% growth driven by solid commercial execution and continued portfolio adoption

AURYON

FY 2026	Sales ($M)	YoY Growth
Total Auryon	$66.9	17.7%

ALPHAVAC

ANGIOVAC

FY 2026	Sales ($M)	YoY Growth
AlphaVac	$15.5	44.1%
AngioVac	$29.5	2.1%
Total Mech Thromb.	**$45.0**	**13.4%**
Unifuse	$4.9	(12.5)%
Total Thrombus Mgmt.	**$49.9**	**10.2%**

NANOKNIFE Irreversible Electroporation (IRE) PROSTATE

FY 2026	Sales ($M)	YoY Growth
Disposables	$25.4	28.7%
Capital	$7.8	61.8%
Total NanoKnife	**$33.1**	**35.2%**

Key Highlights

- **Auryon**: Capped the year with strong double-digit growth, extending its multi-year track record as our hospital atherectomy strategy scales.
- **Mechanical Thrombectomy**: Grew double digits for the full year, with a standout year from AlphaVac.
- **NanoKnife**: Delivered broad-based growth across both probes and capital as prostate adoption accelerates.

Fiscal Year 2027 Guidance

supported by balance sheet strength

FY 2026 Net Sales ($M)



FY 2027 Financial Guidance*

Metric	Current Guidance
Net Sales	**$336.0M - $341.0M**
Med Tech Net Sales Growth	*+12% - 15%*
Med Device Net Sales Growth	*Flat*
Gross Margin	**54% – 55%**
Adjusted EBITDA	**+$13.0M - $16.0M**
Adjusted EPS	**($0.29) – ($0.24)**

*Guidance was issued in conjunction with fiscal Q4 FY 2026 earnings call on July 14, 2026

Strong Product & Clinical Pipeline

Leveraging our leading platforms to fuel innovation, market expansion, and long-term shareholder value in key growth markets

Platform	FY26 & Earlier $7.2B US TAM	FY27 – FY31 $10.9B US TAM
AURYON	Peripheral Artery Disease: $800M US TAM	IVL Indication DVT: $2.8B US TAM Coronary: $900M US TAM
ALPHAVAC ANGIOVAC	Pulmonary Embolism: $2.4B US TAM Right Heart: $280M US TAM	Infective Endocarditis Indication DVT: $2.8B US TAM Left Heart: $760M US TAM
NANOKNIFE Irreversible Electroporation (IRE) PROSTATE	Prostate Cancer: $930M US TAM	BPH: $1.9B US TAM

Ongoing Clinical Initiatives to Support Growth

Initiative	Overview	Purpose
AMBITION BTK	A randomized controlled trial of the Auryon Atherectomy System + balloon angioplasty vs. standard angioplasty alone for below-the-knee lesions with critical limb ischemia (up to 224 patients / 30 sites + 1,500-patient registry).	Increased utilization within the below the knee critical limb ischemia (CLI) disease state
RECOVER-AV	A multi-center, multi-national, single-arm study of the AlphaVac F18[85] System for mechanical thrombectomy in the treatment of acute, intermediate-risk pulmonary embolism (PE).	Increased European adoption
APEX-Return	An IDE-approved study of the AlphaReturn blood management system, evaluating key safety and effectiveness endpoints, including device-related adverse events and procedural outcomes.	Enables collection, filtration, and reinfusion of aspirated blood during thrombectomy; addresses market feedback on blood loss
PAVE	A prospective, single-arm, multicenter feasibility trial that will enroll up to 30 patients with RSIE at up to six U.S. centers. In August 2023, the AngioVac System received an FDA Breakthrough Device designation for the removal of right heart vegetation.	Indication expansion into right-sided infective endocarditis (RSIE)
RELIEF	A feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology, for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).	Indication expansion into benign prostatic hyperplasia (BPH)

Appendix

Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements

(in thousand, except per share data)

	Three Months Ended			
	Actual [1] May 31, 2026 (unaudited)	As Reported [1] May 31, 2025 (audited)	Pro Forma Adjustments [2] May 31, 2025 (unaudited)	Pro Forma May 31, 2025 (unaudited)
Net sales	$ 86,607	$ 80,158	(1)	$ 80,157
Cost of sales (exclusive of intangible amortization)	39,834	37,940	2	37,942
Gross margin	46,773	42,218	(3)	42,215
% of net sales	54.0 %	52.7 %		52.7 %
Operating expenses				
Research and development	8,178	6,590	—	6,590
Sales and marketing	31,123	26,437	—	26,437
General and administrative	10,266	10,236	—	10,236
Amortization of intangibles	2,718	2,588	—	2,588
Acquisition, restructuring and other items, net	4,683	2,155	—	2,155
Total operating expenses	56,968	48,006	—	48,006
Operating loss	(10,195)	(5,788)	(3)	(5,791)
Interest income (expense), net	(105)	3	—	3
Other expense, net	(735)	(325)	—	(325)
Total other expense, net	(840)	(322)	—	(322)
Loss before income tax (benefit) expense	(11,035)	(6,110)	(3)	(6,113)
Income tax (benefit) expense	370	(60)	—	(60)
Net loss	$ (11,405)	$ (6,050)	$ (3)	$ (6,053)
Loss per share				
Basic	$ (0.27)	$ (0.15)		$ (0.15)
Diluted	$ (0.27)	$ (0.15)		$ (0.15)
Weighted average shares outstanding				
Basic	41,696	40,984		40,984
Diluted	41,696	40,984		40,984

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended May 31, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

	Twelve months ended					
	Actual [1] May 31, 2026 (unaudited)	Pro Forma Adjustments [2] May 31, 2026 (unaudited)	Pro Forma May 31, 2026 (unaudited)	As Reported [1] May 31, 2025 (audited)	Pro Forma Adjustments [2] May 31, 2025 (unaudited)	Pro Forma May 31, 2025 (unaudited)
Net sales	$ 320,174	(2)	$ 320,172	$ 292,498	187	$ 292,685
Cost of sales (exclusive of intangible amortization)	145,282	—	145,282	134,793	157	134,950
Gross margin	174,892	(2)	174,890	157,705	30	157,735
% of net sales	54.6 %		54.6 %	53.9 %		53.9 %
Operating expenses						
Research and development	29,447	—	29,447	26,222	—	26,222
Sales and marketing	113,401	—	113,401	103,135	—	103,135
General and administrative	43,691	—	43,691	42,092	—	42,092
Amortization of intangibles	10,682	—	10,682	10,318	—	10,318
Change in fair value of contingent consideration	—	—	—	272	—	272
Acquisition, restructuring and other items, net	17,598	—	17,598	15,620	161	15,781
Total operating expenses	214,819	—	214,819	197,659	161	197,820
Operating loss	(39,927)	(2)	(39,929)	(39,954)	(131)	(40,085)
Interest income (expense), net	(299)	—	(299)	978	—	978
Other income (expense), net	3,926	(5,000)	(1,074)	4,944	(5,500)	(556)
Total other income (expense), net	3,627	(5,000)	(1,373)	5,922	(5,500)	422
Loss before income tax (benefit) expense	(36,300)	(5,002)	(41,302)	(34,032)	(5,631)	(39,663)
Income tax (benefit) expense	442	—	442	(39)	—	(39)
Net loss	$ (36,742)	$ (5,002)	$ (41,744)	$ (33,993)	$ (5,631)	$ (39,624)
Loss per share						
Basic	$ (0.88)		$ (1.01)	$ (0.83)		$ (0.97)
Diluted	$ (0.88)		$ (1.01)	$ (0.83)		$ (0.97)
Weighted average shares outstanding						
Basic	41,526		41,526	40,853		40,853
Diluted	41,526		41,526	40,853		40,853

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the twelve months ended May 31, 2026 and 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss and Diluted Loss Per Share and Pro Forma Adjusted Net Loss and Diluted Loss Per Share

(in thousands, except per share data)

	Three Months Ended			
	Actual May 31, 2026 (unaudited)	As Reported [1] May 31, 2025 (unaudited)	Pro Forma Adjustments [2] May 31, 2025 (unaudited)	Pro Forma May 31, 2025 (unaudited)
Net loss	$ (11,405)	$ (6,050)	$ (3)	$ (6,053)
Amortization of intangibles	2,718	2,588	—	2,588
Acquisition, restructuring and other items, net [3]	4,683	2,155	—	2,155
Tax effect of non-GAAP items [4]	1,206	254	1	255
Adjusted net loss	$ (2,798)	$ (1,053)	$ (2)	$ (1,055)

	Three Months Ended			
	Actual May 31, 2026 (unaudited)	As Reported [1] May 31, 2025 (unaudited)	Pro Forma Adjustments [2] May 31, 2025 (unaudited)	Pro Forma May 31, 2025 (unaudited)
Diluted loss per share	$ (0.27)	$ (0.15)	$ —	$ (0.15)
Amortization of intangibles	0.07	0.06	—	0.06
Acquisition, restructuring and other items, net [3]	0.10	0.05	—	0.05
Tax effect of non-GAAP items [4]	0.03	0.01	—	0.01
Adjusted diluted loss per share	$ (0.07)	$ (0.03)	$ —	$ (0.03)
Adjusted diluted sharecount	41,696	40,984	40,984	40,984

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended May 31, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended May 31, 2026 and 2025.

Reconciliation of Net Loss and Non-GAAP Pro Forma Adjusted Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA

(in thousands)

	Three Months Ended			
	Actual May 31, 2026 (unaudited)	As Reported [1] May 31, 2025 (unaudited)	Pro Forma Adjustments [2] May 31, 2025 (unaudited)	Pro Forma May 31, 2025 (unaudited)
Net loss	$ (11,405)	$ (6,050)	$ (3)	$ (6,053)
Income tax benefit	370	(60)	—	(60)
Interest income (expense), net	105	(3)	—	(3)
Depreciation and amortization	5,597	5,833	—	5,833
Stock based compensation	3,915	1,641	—	1,641
Acquisition, restructuring and other items, net [3]	4,683	2,000	—	2,000
Adjusted EBITDA	$ 3,265	$ 3,361	$ (3)	$ 3,358

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended May 31, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss and Diluted Loss Per Share and Pro Forma Adjusted Net Loss and Diluted Loss Per Share

(in thousands, except per share data)

	Twelve Months Ended					
	Actual [1] May 31, 2026 (unaudited)	Pro Forma Adjustments [2] May 31, 2026 (unaudited)	Pro Forma May 31, 2026 (unaudited)	As Reported [1] May 31, 2025 (unaudited)	Pro Forma Adjustments [2] May 31, 2025 (unaudited)	Pro Forma May 31, 2025 (unaudited)
Net Loss	$ (36,742)	$ (5,002)	$ (41,744)	$ (33,993)	$ (5,631)	$ (39,624)
Amortization of intangibles	10,682	—	$ 10,682	10,318	—	10,318
Change in fair value of contingent consideration	—	—	$ —	272	—	272
Acquisition, restructuring and other items, net [3]	17,598	—	$ 17,598	15,620	161	15,781
Tax effect of non-GAAP items [4]	2,287	1,149	3,436	1,760	1,258	3,018
Adjusted net loss	$ (6,175)	$ (3,853)	$ (10,028)	$ (6,023)	$ (4,212)	$ (10,235)

	Twelve Months Ended					
	Actual [1] May 31, 2026 (unaudited)	Pro Forma Adjustments [2] May 31, 2026 (unaudited)	Pro Forma May 31, 2026 (unaudited)	As Reported [1] May 31, 2025 (unaudited)	Pro Forma Adjustments [2] May 31, 2025 (unaudited)	Pro Forma May 31, 2025 (unaudited)
Diluted loss per share	$ (0.88)	$ (0.13)	$ (1.01)	$ (0.83)	$ (0.14)	$ (0.97)
Amortization of intangibles	0.26	—	0.26	0.25	—	0.25
Change in fair value of contingent consideration	—	—	—	0.01	—	0.01
Acquisition, restructuring and other items, net [3]	0.41	—	0.41	0.38	0.01	0.39
Tax effect of non-GAAP items [4]	0.06	0.04	0.10	0.04	0.03	0.07
Adjusted pro forma diluted loss per share	$ (0.15)	$ (0.09)	$ (0.24)	$ (0.15)	$ (0.10)	$ (0.25)
Adjusted diluted sharecount	41,526	41,526	41,526	40,853	40,853	40,853

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the twelve months ended May 31, 2026 and 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items

(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended May 31, 2026 and 2025.

Reconciliation of Net Loss and Non-GAAP Pro Forma Adjusted Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA

(in thousands)

	Twelve Months Ended					
	Actual [1] May 31, 2026 (unaudited)	Pro Forma Adjustments [2] May 31, 2026 (unaudited)	Pro Forma May 31, 2026 (unaudited)	As Reported [1] May 31, 2025 (unaudited)	Pro Forma Adjustments [2] May 31, 2025 (unaudited)	Pro Forma May 31, 2025 (unaudited)
Net loss	$ (36,742)	$ (5,002)	$ (41,744)	$ (33,993)	$ (5,631)	$ (39,624)
Income tax (benefit) expense	442	—	442	(39)	—	(39)
Interest income (expense), net	299	—	299	(978)	—	(978)
Depreciation and amortization	22,955	—	22,955	25,800	—	25,800
Change in fair value of contingent consideration	—	—	—	272	—	272
Stock based compensation	13,960	—	13,960	9,772	—	9,772
Acquisition, restructuring and other items, net [3]	17,261	—	17,261	12,239	161	12,400
Adjusted EBITDA	$ 18,175	$ (5,002)	$ 13,173	$ 13,073	$ (5,470)	$ 7,603

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the twelve months ended May 31, 2026 and 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

Detail of "Acquisition, Restructuring and Other Items, net"

(in thousands)

	Three Months Ended		Twelve Months Ended	
	May 31, 2026	May 31, 2025	May 31, 2026	May 31, 2025
	(unaudited)	(audited)	(unaudited)	(audited)
Legal [1]	$ 181	$ 309	$ 2,012	$ 715
Mergers and acquisitions [2]	—	—	—	737
Transition service agreement [3]	(17)	(414)	(1,540)	(1,838)
Plant Closure [4]	3,208	1,941	13,119	13,761
CEO Transition [5]	759	—	1,629	—
Other	552	319	2,378	2,245
Total	$ 4,683	$ 2,155	$ 17,598	$ 15,620

(1) Legal expenses related to litigation that is outside the normal course of business.

(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.

(3) Transition services agreement that were entered into with Merit and Spectrum.

(4) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.

(5) CEO retirement and transition expenses related to the CEO search and retention agreements with the Company's executive leadership team.

Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category

(in thousands)

	Three Months Ended					
	Actual May 31, 2026	As Reported [1] May 31, 2025	Pro Forma Adjustments [2] May 31, 2025	Pro Forma May 31, 2025	Actual % Growth	Pro Forma % Growth
	(unaudited)	(audited)	(unaudited)	(unaudited)		
Net Sales						
Med Tech	$ 41,758	$ 35,790	$ —	$ 35,790	16.7%	16.7%
Med Device	44,849	44,368	(1)	44,367	1.1%	1.1%
	$ 86,607	$ 80,158	$ (1)	$ 80,157	8.0%	8.0%
Net Sales						
United States	$ 73,595	$ 67,484	$ (1)	$ 67,483	9.1%	9.1%
International	13,012	12,674	—	12,674	2.7%	2.7%
	$ 86,607	$ 80,158	$ (1)	$ 80,157	8.0%	8.0%

	Twelve Months Ended							
	Actual [1] May 31, 2026	Pro Forma Adjustments [2] May 31, 2026	Pro Forma May 31, 2026	As Reported [1] May 31, 2025	Pro Forma Adjustments [2] May 31, 2025	Pro Forma May 31, 2025	Actual % Growth	Pro Forma % Growth
	(unaudited)	(unaudited)	(unaudited)	(audited)	(unaudited)	(unaudited)		
Net Sales								
Med Tech	$ 149,954	$ —	$ 149,954	$ 126,653	$ —	$ 126,653	18.4%	18.4%
Med Device	170,220	(2)	170,218	165,845	187	166,032	2.6%	2.5%
	$ 320,174	$ (2)	$ 320,172	$ 292,498	$ 187	$ 292,685	9.5%	9.4%
Net Sales								
United States	$ 274,923	$ (2)	$ 274,921	$ 250,983	$ 13	$ 250,996	9.5%	9.5%
International	45,251	—	45,251	41,515	174	41,689	9.0%	8.5%
	$ 320,174	$ (2)	$ 320,172	$ 292,498	$ 187	$ 292,685	9.5%	9.4%

	Three Months Ended					
	Actual May 31, 2026	As Reported [1] May 31, 2025	Pro Forma Adjustments [2] May 31, 2025	Pro Forma May 31, 2025	Actual % Change	Pro Forma % Change
	(unaudited)	(audited)	(unaudited)	(unaudited)		
Med Tech	$ 26,856	$ 21,117	$ —	$ 21,117	27.2 %	27.2 %
Gross margin % of sales	64.3 %	59.0 %		59.0 %		
Med Device	$ 19,917	$ 21,101	$ (3)	$ 21,098	(5.6)%	(5.6)%
Gross margin % of sales	44.4 %	47.6 %		47.6 %		
Total	$ 46,773	$ 42,218	$ (3)	$ 42,215	10.8 %	10.8 %
Gross margin % of sales	54.0 %	52.7 %		52.7 %		

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended May 31, 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sale and discontinuation of the Businesses.

	Twelve Months Ended							
	Actual [1] May 31, 2026	Pro Forma Adjustments [2] May 31, 2026	Pro Forma May 31, 2026	As Reported [1] May 31, 2025	Pro Forma Adjustments [2] May 31, 2025	Pro Forma May 31, 2025	Actual % Change	Pro Forma % Change
	(unaudited)	(unaudited)	(unaudited)	(audited)	(unaudited)	(unaudited)		
Med Tech	$ 95,356	$ —	$ 95,356	$ 78,515	$ —	$ 78,515	21.4 %	21.4 %
Gross margin % of sales	63.6 %		63.6 %	62.0 %		62.0 %		
Med Device	$ 79,536	$ (2)	$ 79,534	$ 79,190	$ 30	$ 79,220	0.4 %	0.4 %
Gross margin % of sales	46.7 %		46.7 %	47.7 %		47.7 %		
Total	$ 174,892	$ (2)	$ 174,890	$ 157,705	$ 30	$ 157,735	10.9 %	10.9 %
Gross margin % of sales	54.6 %		54.6 %	53.9 %		53.9 %		

(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the divestiture of the Dialysis and BioSentry Businesses, the sale of the PICCs and Midlines Businesses and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") for the twelve months ended May 31, 2026 and 2025.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.